Clinical significance of positive anti-neutrophil cytoplasmic antibodies without evidence of anti-neutrophil cytoplasmic antibodies-associated vasculitis

被引:13
作者
Bornstein, Gil [1 ,2 ]
Ben-Zvi, Ilan [3 ,4 ,5 ]
Furie, Nadav [3 ,4 ,5 ]
Grossman, Chagai [3 ,4 ,5 ]
机构
[1] Tel Aviv Sourasky Med Ctr, Dept Internal Med B, Tel Aviv, Israel
[2] Tel Aviv Sourasky Med Ctr, Rheumatol Unit, Tel Aviv, Israel
[3] Chaim Sheba Med Ctr, Dept Internal Med F, Ramat Gan, Israel
[4] Chaim Sheba Med Ctr, Rheumatol Unit, Ramat Gan, Israel
[5] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
关键词
anti-neutrophil cytoplasmic antibodies; enzyme-linked immunosorbent assay; vasculitis; SYSTEMIC VASCULITIS; ANCA; AUTOANTIBODIES; DIAGNOSIS; ELISA; ENDOCARDITIS; ASSAYS;
D O I
10.1111/1756-185X.13483
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim Anti-neutrophil cytoplasmic antibodies (ANCA) have a role in the diagnostic workup of ANCA-associated vasculitis. However, the clinical significance of positive ANCA in the absence of vasculitis is yet to be determined. Therefore, we sought to investigate the clinical spectrum and rate of patients with a positive ANCA without evidence of vasculitis. Methods Retrospective analysis of patients positive for cytoplasmic ANCA (C-ANCA) and proteinase 3 (PR3) or P-ANCA and myeloperoxidase (MPO) between 2007 and 2016 in the Chaim Sheba Medical Center, Israel. The proportion of patients who had no evidence of vasculitis among all patients with a positive C-ANCA/PR3 or P-ANCA/MPO was calculated according to tertiles of enzyme-linked immunosorbent assay (ELISA) antibody levels. Results Among 113 patients who tested positive for C-ANCA/PR3 or P-ANCA/MPO, 68 (60.1%) had no evidence of vasculitis. ELISA antibody titers were significantly higher among patients with vasculitis than those without (6.2 vs 3.2, for C-ANCA/PR3 and 5.4 vs 2.6 for P-ANCA/MPO, P < 0.05). The proportion of patients without vasculitis among all patients with a positive C-ANCA/PR3 and among all patients with a positive P-ANCA/MPO declined in parallel to the increases in ELISA antibody level tertiles (96%, 57% and 22% in the 1st, 2nd and highest tertiles, respectively, for patients with C-ANCA/PR3 patients and 100%, 66% and 20% in the 1st, 2nd and highest tertiles, respectively, for patients with P-ANCA/MPO). Conclusion A significant proportion of patients with a positive C-ANCA/PR3 or P-ANCA/MPO do not have evidence of vasculitis, particularly those with low-medium ELISA antibody titers. Using a higher threshold of ANCA titers may be required to improve specificity.
引用
收藏
页码:940 / 945
页数:6
相关论文
共 50 条
  • [21] Anti-neutrophil cytoplasmic antibodies (ANCA): Their usefulness in autoimmune vasculitis prognosis
    Cardinalli, A
    Etchevez, P
    Pizzimenti, MC
    Griemberg, G
    ACTA BIOQUIMICA CLINICA LATINOAMERICANA, 1996, 30 (03): : 123 - 130
  • [22] Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis
    Sinico, Renato A.
    Di Toma, Luca
    Radice, Antonella
    AUTOIMMUNITY REVIEWS, 2013, 12 (04) : 477 - 482
  • [23] Anti-Neutrophil Cytoplasmic Antibodies Stimulate Release of Neutrophil Microparticles
    Hong, Ying
    Eleftheriou, Despina
    Hussain, Abdullah A. K.
    Price-Kuehne, Fiona E.
    Savage, Caroline O.
    Jayne, David
    Little, Mark A.
    Salama, Alan D.
    Klein, Nigel J.
    Brogan, Paul A.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (01): : 49 - 62
  • [24] Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis
    Hagen, EC
    Daha, MR
    Hermans, J
    Andrassy, K
    Csernok, E
    Gaskin, G
    Lesavre, P
    Lüdemann, J
    Rasmussen, N
    Sinico, RA
    Wiik, A
    van der Woude, FJ
    KIDNEY INTERNATIONAL, 1998, 53 (03) : 743 - 753
  • [25] Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis
    Koukoulaki, M
    Jayne, DRW
    NEPHRON CLINICAL PRACTICE, 2006, 102 (3-4): : C100 - C107
  • [26] Clinical usefulness of anti-neutrophil cytoplasmic antibodies in childhood systemic lupus erythematosus
    Cardinalli, Antonio
    Ginaca, Alejandra
    Espada, Graciela
    Cristina Pizzimenti, Maria
    Emilia Rivas, Maria
    Leggire, Lina
    Griemberg, Gloria
    ACTA BIOQUIMICA CLINICA LATINOAMERICANA, 2013, 47 (01): : 145 - 153
  • [27] The clinical presentation and therapy of diseases related to anti-neutrophil cytoplasmic antibodies (ANCA)
    Weiner, Maria
    Segelmark, Marten
    AUTOIMMUNITY REVIEWS, 2016, 15 (10) : 978 - 982
  • [28] ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCA) IN LUPUS NEPHRITIS
    Ditto, M.
    Sinico, R. A.
    Trezzi, B.
    Sarzi-Puttini, P.
    Moroni, G.
    Raffiotta, F.
    Messa, P.
    Quaglini, S.
    Radice, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S94 - S95
  • [29] CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis
    Plinio R Hurtado
    Lisa Jeffs
    Jodie Nitschke
    Mittal Patel
    Ghafar Sarvestani
    John Cassidy
    Pravin Hissaria
    David Gillis
    Chen Au Peh
    BMC Immunology, 9
  • [30] Pathogenesis of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis
    Savage, C. O. S.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2011, 164 : 23 - 26